{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:08:52Z","timestamp":1778476132788,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jid.2025.06.1293","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:07:50Z","timestamp":1754435270000},"page":"2936-2937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing Roflumilast and the Emerging Landscape of Phosphodiesterase 4 Inhibition in Psoriasis"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Luis","family":"Puig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.06.1293_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004704","article-title":"Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases","volume":"10","author":"Aringer","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.jid.2025.06.1293_bib2","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1016\/j.jid.2025.04.034","article-title":"Oral Roflumilast suppresses proinflammatory cytokine signaling and reduces CD4+ T-cell and neutrophil infiltration in psoriasis","volume":"145","author":"Baez","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.06.1293_bib3","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1007\/s13555-023-01054-3","article-title":"Next generation PDE4 inhibitors that selectively target PDE4B\/D subtypes: a narrative review","volume":"13","author":"Blauvelt","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2025.06.1293_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/pharmaceutics17010091","article-title":"Exploring the therapeutic landscape: a narrative review on topical and oral Phosphodiesterase-4 inhibitors in dermatology","volume":"17","author":"Carmona-Rocha","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jid.2025.06.1293_bib5","article-title":"Efficacy and safety of oral Roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO)","volume":"30","author":"Gyldenl\u00f8ve","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jid.2025.06.1293_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2025.2464107","article-title":"Oral Roflumilast for psoriasis: a real-world 24-week prospective cohort study","volume":"36","author":"L\u00e9","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jid.2025.06.1293_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.06.1293_bib8","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.06.1293_bib9","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jid.2024.10.597","article-title":"Chemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors","volume":"145","author":"Wang","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.06.1293_bib10","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Warren","year":"2017","journal-title":"Lancet"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25018573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25018573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:23:27Z","timestamp":1778473407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X25018573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0022202X25018573"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.06.1293","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing Roflumilast and the Emerging Landscape of Phosphodiesterase 4 Inhibition in Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.06.1293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.04.034","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}